Home Biosimilar Antibodies Protein Tyrosine Kinase HER2 null Patritumab (Anti-ERBB3 / HER3) For research use only.
Not for use in humans.

Patritumab (Anti-ERBB3 / HER3)

Synonyms: Human Anti-ERBB3 Recombinant Antibody

Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab, potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.

Patritumab (Anti-ERBB3 / HER3)

Click to purchase the isotype control of Patritumab (Anti-ERBB3 / HER3)

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 13.58mg/ml Endotoxin Level: ＜1EU/mg
99

Choose Selective HER2 Inhibitors

Name Citation HER2 Others
Canertinib (CI-1033) 46 EGFR
CP-724714 107
Sapitinib (AZD8931) 46 ErbB3,EGFR
CUDC-101 22 EGFR,HDAC,HDAC1
Mubritinib (TAK 165) 38
AEE788 (NVP-AEE788) 13 EGFR,c-Abl,FLT1
AC480 (BMS-599626) 10 HER1,HER4
TAK-285 4 EGFR/HER1,HER4,MEK1
Tyrphostin AG 879 3 Trk
Poziotinib 33 HER1,HER4
HER2-Inhibitor-1
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab, potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.

Product Details

CAS No. 1262787-83-6
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac，pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Patritumab (Anti-ERBB3 / HER3) | Patritumab (Anti-ERBB3 / HER3) supplier | purchase Patritumab (Anti-ERBB3 / HER3) | Patritumab (Anti-ERBB3 / HER3) cost | Patritumab (Anti-ERBB3 / HER3) manufacturer | order Patritumab (Anti-ERBB3 / HER3) | Patritumab (Anti-ERBB3 / HER3) distributor